Bright Minds Biosciences Cash Flow Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019
Period Ending	Jun '25 Jun 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2019
Net Income	-8.92	-2.8	-7.37	-14.96	-8.65	-0.48	Upgrade
Depreciation & Amortization	0.13	0.07	0.07	0.01	-	-	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	0	-	-	Upgrade
Stock-Based Compensation	2.32	0.84	1.15	0.9	0.88	0.16	Upgrade
Other Operating Activities	-0.88	-0	0.07	-0.26	0.14	-	Upgrade
Change in Accounts Payable	0.36	0.24	-1.2	0.77	0.51	0.11	Upgrade
Change in Other Net Operating Assets	-0.91	-0.2	0.26	-0.04	-0.2	-0.08	Upgrade
Operating Cash Flow	-7.89	-1.85	-7.02	-13.59	-7.32	-0.29	Upgrade
Long-Term Debt Repaid	-	-0.09	-0.09	-0.01	-	-	Upgrade
Net Debt Issued (Repaid)	-0.1	-0.09	-0.09	-0.01	-	-	Upgrade
Issuance of Common Stock	49.82	0.9	1.47	6	27.84	1.01	Upgrade
Other Financing Activities	2.51	0	0.8	-0.8	-1.79	-	Upgrade
Financing Cash Flow	52.23	0.81	2.19	5.2	26.06	1.01	Upgrade
Foreign Exchange Rate Adjustments	0.86	0.01	-0.05	0.26	0.22	-	Upgrade
Net Cash Flow	45.2	-1.03	-4.88	-8.13	18.96	0.72	Upgrade
Levered Free Cash Flow	-3.46	-0.69	-4.22	-7.58	-3.85	-0.1	Upgrade
Unlevered Free Cash Flow	-3.46	-0.68	-4.22	-7.58	-3.85	-0.1	Upgrade
Change in Working Capital	-0.54	0.04	-0.94	0.72	0.31	0.03	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.